Eight-year outcomes of testosterone suppression plus enzalutamide or a nonsteroidal antiandrogen for metastatic hormone-sensitive prostate cancer (ENZAMET; ANZUP 1304)

Annals of Vascular Surgery · Elsevier

Аннотация

Publication date: November 2026 Source: Annals of Oncology, Volume 37, Issue 11 Author(s): A.Y. Zhang, H. Thomas, S. Begbie, L. Cheung, K.N. Chi, S. Chowdhury, M. Frydenberg, C. Herberstein, L.G. Horvath, A.M. Joshua, N.J. Lawrence, G. Marx, J. McCaffrey, R. McDermott, R.A. McLaughlin, S.A. North, F. Parnis, W. Parulekar, D.W. Pook, M.N. Reaume

Читать у издателя →

Похожие статьи